publication date: May. 30, 2014


Boyd.html

Boyd’s Rebuttal to DePinho’s Letter to the AAUP

Douglas Boyd, a professor at MD Anderson, sent his own letter to the American Association of University Professors, responding to DePinho’s version of events.

Boyd is chair of MD Anderson’s Faculty Senate Promotion & Tenure Issues Committee.

The full text of the letter, addressed to Gregory Scholtz, AAUP associate secretary and director of the Department of Academic Freedom, Tenure and Governance, follows:


Dear Dr. Scholtz,

I feel that I must respond to the letter from Dr. DePinho in response to yours of May 13, 2014 since there are several inaccuracies and the administration skirts the important issues at hand. Relevant sections are extracted verbatim and my response follows each.

1) Dr. Buchholz informed Dr. Mehta (Oct 11, 2012), “based on my review of this matter including your current lack of expected external funding…my decision that the non-renewal…should be upheld”

Response: The review by the Faculty Senate Promotion Tenure Committee Issues committee determined (a) Dr. Mehta was well funded by the NIH (i.e. external funding) over the six years (grants NIH CA135218 and CA092115 and bringing in over $770,000) through 2012 (i.e. at the time he was reviewed for tenure renewal) not to mention an additional $725,000 from other peer-reviewed (also external) grants.

Importantly, with the extremely competitive nature of national funding in the current era (-7% of applications are funded), many of our faculty do NOT fulfil the 40% salary requirement.

Indeed, the review by our Faculty Senate Promotion Tenure Committee Issues committee showed two faculty members who were Continue reading 40-22 DePinho Explains Tenure Decision, Professors Dispute Key Details 3

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.